Clinical Trials Logo

Tuberculosis, Pulmonary clinical trials

View clinical trials related to Tuberculosis, Pulmonary.

Filter by:

NCT ID: NCT05122624 Completed - Clinical trials for Tuberculosis, Pulmonary

A Clinical Risk Score for Early Management of TB in Uganda

PredicTB
Start date: November 10, 2021
Phase: N/A
Study type: Interventional

Although curative treatment exists, tuberculosis (TB) remains the leading cause of infectious mortality worldwide - often because people seek care for TB symptoms in highly resource-constrained clinics that cannot provide same-day diagnostic testing. The research team has developed an easy-to-use clinical risk score that, if implemented in these settings, might help clinicians identify patients at high risk for TB and thereby start treatment for those patients on the same day. This study will investigate the effectiveness and implementation of this score in four peri-urban clinics in Uganda, providing critical pragmatic data to inform (or halt) the design of a definitive large-scale cluster randomized trial.

NCT ID: NCT05097638 Completed - Clinical trials for Pulmonary Tuberculoses

Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.

Start date: January 20, 2018
Phase:
Study type: Observational

Some of pulmonary tuberculous patients who completed their medication course experience lung function impairment

NCT ID: NCT05073965 Completed - Clinical trials for Tuberculosis, Pulmonary

Vitamin D Supplementation Effect In Children With Pulmonary Tuberculosis Treatment

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

This study aims to evaluate the vitamin D supplementation effect to improve clinical outcomes in children with pulmonary tuberculosis treatment. This randomized, double-blind control trial with a cohort design was conducted in West Borneo from December 2020 - July 2021. A Total 84 patients met the inclusion criteria; aged 6 to 18 years old, newly diagnosed with pulmonary tuberculosis with vitamin D insufficiency. Only 80 patients completed the six months follow-up. The intervention was 1,000 IU vitamin D or placebo for six months treatment. Comparison of clinical conditions and nutritional status are analyzed statistically.

NCT ID: NCT05065905 Completed - Clinical trials for Human Immunodeficiency Virus

Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis

MSPB_TB
Start date: January 19, 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the rational of its use.

NCT ID: NCT04995406 Completed - Clinical trials for TUBERCULOSIS, PULMONARY

Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis

ISIT-TB
Start date: January 3, 2022
Phase:
Study type: Observational

ISIT-TB Prototype is a diagnostic assay based on a transcriptional blood signature suggestive of the detection of Mycobacterium tuberculosis.

NCT ID: NCT04973371 Completed - Clinical trials for Tuberculosis, Pulmonary

Acceptability and Feasibility of Home-based TB Testing

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This study aims to evaluate the utility of home-based point-of-care TB testing for early diagnosis and linkage to care of household contacts of TB patients, addressing the need for active case finding and early detection of infectious TB. The investigators propose an exploratory study to 1) investigate the acceptability and feasibility of home-based TB testing of household contacts using a new portable GeneXpert point-of-care (PoC) platform, and 2) determine the potential impact of such a home-based testing program on early detection of TB disease and linkage-to-care (LTC).

NCT ID: NCT04938596 Completed - Tuberculosis Clinical Trials

Airborne Preventive Measures to Reduce New TB Infections in Household Contacts

TBMask
Start date: October 4, 2021
Phase: N/A
Study type: Interventional

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be set up, to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary health care in a high TB incidence area in Santiago, Chile.

NCT ID: NCT04874948 Completed - Tuberculosis Clinical Trials

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

Start date: September 21, 2021
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in 4 healthy adult male subjects

NCT ID: NCT04865536 Completed - Tuberculosis Clinical Trials

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Start date: February 16, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT ID: NCT04857814 Completed - Cystic Fibrosis Clinical Trials

Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition. There are also limited ways to check the health of patients with respiratory conditions at home and during the time between medical appointments. The ADAMM-RSMTM device records heart rate, breathing rate, temperature, cough and activity while wearing it. This study will test participants willingness to wear the device and perform ongoing monitoring to assess the possibility to predict the onset and increases in severity of their lung conditions.